Bicocca Open Archive

Logo unimib boa
LUPPI, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.858
EU - Europa 5.273
AS - Asia 3.599
SA - Sud America 216
AF - Africa 42
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 3
Totale 19.005
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.689
SG - Singapore 1.650
IT - Italia 1.226
RU - Federazione Russa 1.225
IE - Irlanda 916
HK - Hong Kong 829
CN - Cina 674
DE - Germania 624
SE - Svezia 502
GB - Regno Unito 214
UA - Ucraina 190
BR - Brasile 185
ID - Indonesia 170
CA - Canada 125
FR - Francia 96
VN - Vietnam 69
NL - Olanda 55
AT - Austria 50
FI - Finlandia 46
IN - India 39
MX - Messico 36
TR - Turchia 36
BE - Belgio 28
DK - Danimarca 28
JP - Giappone 28
PK - Pakistan 17
CH - Svizzera 14
CZ - Repubblica Ceca 13
ZA - Sudafrica 12
MA - Marocco 11
TW - Taiwan 11
AU - Australia 10
ES - Italia 10
CL - Cile 8
IR - Iran 7
PH - Filippine 7
AR - Argentina 6
MN - Mongolia 6
PE - Perù 6
RO - Romania 6
AZ - Azerbaigian 5
EG - Egitto 5
PL - Polonia 5
BD - Bangladesh 4
BG - Bulgaria 4
CO - Colombia 4
IL - Israele 4
KG - Kirghizistan 4
KR - Corea 4
NZ - Nuova Zelanda 4
SA - Arabia Saudita 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
EU - Europa 3
JO - Giordania 3
LV - Lettonia 3
MU - Mauritius 3
NG - Nigeria 3
PT - Portogallo 3
UZ - Uzbekistan 3
AL - Albania 2
AM - Armenia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
GE - Georgia 2
HN - Honduras 2
KZ - Kazakistan 2
MM - Myanmar 2
MT - Malta 2
PS - Palestinian Territory 2
PY - Paraguay 2
RS - Serbia 2
TJ - Tagikistan 2
VE - Venezuela 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
EE - Estonia 1
GR - Grecia 1
IQ - Iraq 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
TH - Thailandia 1
YE - Yemen 1
Totale 19.005
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.515
Fairfield 1.223
Singapore 1.221
Dublin 898
Hong Kong 827
Wilmington 596
Ashburn 558
Woodbridge 518
Seattle 501
Chandler 474
Frankfurt am Main 450
Houston 441
Cambridge 390
Princeton 370
Santa Clara 329
New York 324
Milan 298
Dearborn 272
Jakarta 167
Altamura 160
Nanjing 154
Jacksonville 147
Lawrence 139
Beijing 84
Moscow 83
Shanghai 83
Ottawa 79
San Diego 76
Andover 65
Rome 63
Dong Ket 46
London 45
Nuremberg 43
Boardman 42
Hebei 41
Helsinki 37
Shenyang 37
Council Bluffs 35
Fremont 34
Monza 33
Nanchang 33
Guangzhou 31
Vienna 30
Toronto 28
Chicago 24
Jiaxing 23
Brussels 22
Jinan 22
Norwalk 21
Los Angeles 20
Hefei 19
Bari 18
Tianjin 18
Genoa 17
Kocaeli 17
Munich 16
Changsha 15
Lissone 15
São Paulo 15
Naples 14
Mexico City 13
Ningbo 13
Düsseldorf 12
Bologna 11
Brasília 11
Zurich 11
Redmond 10
Saint Louis 10
Brno 9
Carate Brianza 9
Catania 9
Zhengzhou 9
Falls Church 8
Lappeenranta 8
Washington 8
Amsterdam 7
Beauharnois 7
Brescia 7
Castrolibero 7
Cesate 7
Palermo 7
Casorate Primo 6
Desio 6
Gallarate 6
Laurel 6
Mumbai 6
Pune 6
Tokyo 6
Ankara 5
Baku 5
Belo Horizonte 5
Duncan 5
Edmonton 5
Faisalabad 5
Fuzhou 5
Groningen 5
Kunming 5
Lodi 5
New Bedfont 5
Padova 5
Totale 13.611
Salva come PNG Salva come JPEG
Nome #
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 304
Early referral to palliative care services in patients with IPF: A tool to take a step forward 296
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 246
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 232
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 222
Janus-faced amiodarone-induced pneumopathy 218
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 207
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 204
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 197
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 191
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 190
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 184
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 182
Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study 180
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 175
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 175
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 167
Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis 162
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 161
Cigarette smoke upregulates clusterin expression and apoptosis in human bronchial epithelial cells 159
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 159
Cigarette smoke extract (CSE) induces clusterion expression in human lung fibroblasts. 158
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 157
What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures 156
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 154
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 147
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 137
Diagnosis of asthma and copd 135
Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (instage) 134
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 131
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 128
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 127
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 125
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 124
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 121
Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis 120
A multidisciplinary approach to screen the post-COVID-19 conditions 120
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 120
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? 120
Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis 119
Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease 119
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment 119
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 117
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 116
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 115
Management of Idiopathic Pulmonary Fibrosis 114
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 114
Interstitial pneumonitis with autoimmune features (IPAF): A work in progress 113
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 112
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: A multicenter prospective study 112
Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study 112
Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders 111
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 110
Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study 109
Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione 109
Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre 109
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial 109
Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic 107
Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors 107
The Multiple Components of COPD 106
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 106
Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay 105
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A case report 105
Sarcoidosis: challenging diagnostic aspects of an old disease 105
Bronchial hyperresponsiveness in asthmatic adults - A long-term correlation study 104
Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation 104
Mindfulness-based stress reduction in patients with interstitial lung diseases: A pilot, single-centre observational study on safety and efficacy 102
Update in chronic obstructive pulmonary disease 2006 102
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 102
Pulmonary comorbidities associated with chronic obstructive pulmonary disease | [BPCO e altre malattie polmonari croniche] 101
Update in chronic obstructive pulmonary disease 2005 100
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study 100
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 99
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases 98
Interstiziopatia polmonare non classificabile o secondaria a connettivite indifferenziata. importanza e difficoltà di una diagnosi differenziale 97
Complex chronic co-morbidities of COPD 95
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature 95
Definizione, classificazione ed eziopatogenesi 95
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 94
Pathophysiology of exacerbations of chronic obstructive pulmonary disease 93
Non-steroid agents for idiopathic pulmonary fibrosis 93
In vitro increase of epidermal growth factor receptor expression in the lung epithelial cells after exposure to cigarette smoke 93
Rheumatoid arthritis related interstitial lung disease 93
Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways 92
EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to egfr inhibitors 92
Clusterin (CLU) and lung cancer 92
Lung complications of Sjogren syndrome 92
Progression and prognosis of interstitial pneumonia with autoimmune features: a longitudinal, prospective, multi-centre study 91
Pathology of COPD and asthma 91
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells 90
Predicting the future of patients with idiopathic pulmonary fibrosis: another step forward 89
The big clinical trials in idiopathic pulmonary fibrosis 89
Prognostic role of clusterin in resected adenocarcinomas of the lung 89
To BAL or not to BAL: Is this a problem in diagnosing IPF? 87
Treatment of chronic obstructive pulmonary disease and its comorbidities 87
Management of idiopathic pulmonary fibrosis 87
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 87
Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke 86
Broncopneumopatia cronica ostruttiva: Patogenesi 85
Genetic testing in diffuse parenchymal lung disease 85
Totale 12.776
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.517
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.517
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020452 0 0 0 0 0 0 0 0 0 179 157 116
2020/20212.858 86 172 472 354 309 234 206 286 146 233 155 205
2021/20221.845 154 208 190 193 90 120 84 124 98 95 160 329
2022/20232.726 417 725 264 172 169 468 38 134 166 24 84 65
2023/20242.467 55 66 93 76 330 607 547 85 281 33 35 259
2024/20255.741 400 1.168 430 326 609 308 546 218 687 1.049 0 0
Totale 19.984